Capecitabine: An *In-vitro* Comparison between the Branded Xeloda® 500 Mg and its Intended Copy Capeda 500 Mg

Mubarak Nasser AlAmeri*, Simon Abi Aad1, Arthur Tucker1 and Atholl Johnston1

1William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London E1CM 6BQ, UK
2St. Luke’s-Roosevelt Hospital Centre, Department of Medicine, Manhattan, New York, USA

Abstract

**Introduction:** Dissolution is an example of *in-vitro* test which can be used to identify formulations that may present potential bioequivalence problems. It is defined as the amount of substance that goes into solution per unit time under standardised conditions of liquid/solid interface, solvent composition and temperature. It is considered one of the most important tools to predict the *in-vivo* bioavailability and in some cases replacing clinical studies to determine bioequivalence.

**Aim:** To compare the differences in the dissolution behaviour between two anticancer formulations, Xeloda® 500 mg (reference product) and Capeda 500 mg (test product).

**Methods:** Four replicates for each batch of the tested medicines were carried out using a PT-DT70 dissolution tester (Pharma Test) to detect any differences in their dissolution behaviour. Samples at nine time intervals were tested according to the US Pharmacopeia with the rate of dissolution determined by ultra-violet spectrophotometry.

**Results:** All the tested medicines complied with the pharmacopeial specifications, the EMA and the FDA guidance for industry when achieved 85% dissolution in 60 minutes. However, Capeda 500 mg (test product) showed slower, different and incomplete dissolution rate compared to Xeloda® 500 mg (reference product) at both 60 and 120 minutes. Other visual differences in the weight, size, clarity of solution, presence of un-dissolved residue and particles during the dissolution test were also detected.

**Conclusion:** Results in this study clearly raise a question about the interchangeability between Xeloda® 500 mg and its Intended copy Capeda 500 mg. Awareness of these scientific concerns should be considered when a clinical choice between these two drugs is required. Differences between the innovator and copy medicines with regard to pharmacokinetics, clinical efficacy and safety may exist. Thereby, patients’ monitoring after performing drug substitution of these two medicines is strongly recommended.

Keywords: Dissolution test; Differences between the branded and generic medicines; Absorption and dissolution methods; Capecitabine; Xeloda®; Capeda

Introduction

Generic drug usually means a drug that has the same qualitative and quantitative composition of the active ingredient and the same pharmaceutical form as the reference branded drug, and whose bioavailability with the reference drug has been demonstrated by an appropriate bioequivalence study [1]. Generic substitution is defined as switching between a branded product and a generic version of the same drug (such as switching from Taxotere® to docetaxel) [2]. Promoting generic substitution from multiple sources into the healthcare system is aimed at maximising population health subject to improve the overall healthcare delivery systems [3]. This strategy of drug substitution is proven to be effective since it is often easier to intervene on the expenditure of medicines because of their identified cost [4-6]. However, this has been accompanied by a variety of problems of which the most critical is the widespread distribution of substandard generics and fake drug products. As a consequence, health care providers and patients are usually concerned when selecting one drug from among several bioequivalent ones during the treatment regime [7, 8].

Dissolution is an example of *in-vitro* test which can be used to identify formulations that may present potential bioequivalence problems. It is defined as the amount of substance that goes into solution per unit time under standardised conditions of liquid/solid interface, solvent composition and temperature [9]. It is considered one of the most important tools to predict the *in-vivo* bioavailability and in some cases replacing clinical studies to determine bioequivalence [10]. Dissolution is considered as the rate limiting step for a drug to be absorbed from solid dosage form following oral administration. It is the process of transporting the drug substances from the gastrointestinal lumen into the systemic circulation [11]. Absorption is the first step before the distribution, metabolism and elimination (ADME) of drugs in the human body. It usually depends on the stages of disintegration, disaggregation, drug release from the pharmaceutical form, its dissolution under physiological conditions and permeability through the biological membranes, (Figure 1) [12, 13].

In the cases when the *in-vitro* results fail to predict the *in-vivo* performance of a drug product, larger clinical studies are needed to assess the product bioavailability, thus additional cost will be added to the drug development expenses [14]. Therefore, dissolution is considered one of the most important quality control tests performed on pharmaceutical dosage forms and validation of dissolution methods and it is an important part of good manufacturing practice [9]. The importance of dissolution testing, for example, has recently directed the UK MHRA (Medicines and Healthcare products Regulatory Agency) to suspend the license of the generic Teva (levothyroxine 100

*Corresponding author: Mubarak N. AlAmeri, Clinical Pharmacology, Barts and The London, Charterhouse Square, London, EC1M 6BQ, UK, Tel: +44-20-7882 3413; Fax: +44-20-7882 3408; E-mail: m.al-ameri@qmul.ac.uk

Received May 23, 2012; Accepted August 21, 2012; Published August 23, 2012

Citation: AlAmeri MN, Aad SA, Tucker A, Johnston A (2012) Capecitabine: An *In-vitro* Comparison between the Branded Xeloda® 500 Mg and its Intended Copy Capeda 500 Mg. Med chem 2: 112-118. doi:10.4172/2161-0444.1000125

Copyright: © 2012 AlAmeri MN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Capecitabine is an oral pro-drug of 5-fluorouracil (5-FU) which is indicated as anticancer for the treatment of metastatic breast, oesophagogastric and colorectal cancers [17,18]. Unlike the intravenous chemotherapeutic agent 5-FU, Capecitabine is tumor-specific as it generates 5-FU preferentially in tumor tissue [19-21]. 5-fluorouracil/leucovorin (5-FU/LV) was the historical mainstream of treatment of many cancers. This tumor-selective activation of Capecitabine potentially provides tumor-targeted therapy with improved efficacy and reduced toxicity. In addition, Capecitabine’s oral administration regimen provides convenient, patient-orientated treatment in a home-based setting and avoids catheter-related complications [22-24]. Compared with 5-FU, Capecitabine has demonstrated superior response rate, equivalent time to progression and overall survival [25], favorable safety profile [26] and cost savings by fewer hospitalisations for the management of treatment-related adverse events [22]. Xeloda is the branded copy of capecitabine and Capeda is an intended copy of Xeloda which was marketed in Lebanon in 2010, three years before the loss of Xeloda’s patent in the EMA region for 2013 [27,28] (Figure 2).

Breast cancer is the most common malignant disease in women which is considered a public health issue on a global scale. It is considered the second most common cancer in the world and the most common cancer among women [29]. In Europe, in 2004, there was an estimate of 2.9 million new cases of breast cancer and 1.7 million deaths each year [30]. In the US, 28% of the estimated cancer cases with US women in 2010 were breast cancer [31]. Gastric cancer is the second most common cause of cancer-related death in the world – killing around 800,000 people each year, yet it is only the fourth most commonly diagnosed cancer – around one million people are diagnosed each year. The incidence of gastric cancer varies hugely geographically, with a much bigger prevalence in Eastern countries than in the West, and between men and women with men more prone to stomach cancer than women [32]. Similarly the colorectal cancer which remains the third most common cancer among male and females in the US and the most common cause of death [33]. In Europe, the incidence of colorectal cancer is one in 20 [34].

**Objective**

The aim of this study was to compare the differences in dissolution rate of solid dosage forms between Xeloda® 500 mg as the innovators (reference products) to its intended copy Capeda 500 mg (test products).
of measurements obtained from multiple sampling of the same homogeneous sample under the same conditions. Repeatability expresses the precision under the same operating conditions over a short interval of time. Reproducibility expresses the precision between laboratories, in this study standardised procedures from pharmacopoeias was included [39].

**Results**

The volume of the dissolution medium was kept constant and corrected mathematically using Microsoft Office Excel 2007 and Minitab 16 (Minitab Inc, Pennsylvania, PA, USA). The result of this study was expressed as % [95% Confidence Intervals (CI)]. Variations were evaluated using the one-way analysis of variance (ANOVA) and P ≤ 0.05 was considered statistically significant. Dissolution profile compares the percentage of a drug substances dissolved relating to time and represents an alternative to assessment of solid forms before clinical tests [12].

The dissolution rate of Xeloda® 500 mg (branded medicine) compared to Capeda (intended copy medicine) at 60 minutes, (Table 3 and Table 4).

When comparing the dissolution rate between Xeloda® 500 mg to its generic counterpart Capeda 500 mg at 60 minutes, the generic medicine showed a statistically significant difference in the dissolution behaviour (P=0.003). Capeda 500 mg showed much slower and different dissolution behaviour than its branded counterpart. When 100% of the reference Xeloda® 500 mg dissolved at 60 minutes, only 86% (95% CI 80-93) of its intended copy Capeda 500 mg dissolved (Table 5).

The dissolution rate of copy medicines compared to their branded counterpart at 120 minutes are shown in (Table 6 and Table 7).

When comparing the dissolution rate between Xeloda® 500 mg to its intended copy Capeda 500 mg at 120 minutes, the intended copy also showed a statistically significant difference in the dissolution behaviour (P=0.008), (Figure 3). Capeda 500 mg showed different and incomplete dissolution compared to its branded counterpart medicine. When 100% of the branded Xeloda® 500 mg dissolved in 120 minutes, only 90% (95% CI 84-96) of its generic counterpart’s Capeda 500 mg dissolved (Table 8).

**Visual differences detected between the branded Xeloda® 500 mg and its intended copy Capeda 500 mg during the dissolution test**

There were some visual differences detected between the branded Xeloda 500 mg and its intended copy Capeda 500 mg during the dissolution test. For example, there were differences in the weight between both tested drugs. This was weighted by Sartorius AZ64 Research Analytical Weighing Balance. The average weight of Xeloda® 500 mg was 0.64 g compared to 0.99 g of Capeda 500 mg. Differences in the tablet size were also detected between both tested drugs. The tablet size of Xeloda® 500 mg was 14.47 mm (length)×7.00 mm (width)×4.12 mm (depth) compared to 18.22 mm (length)×7.87 mm (width)×4.71 mm (depth).

### Table 1: Characteristics of the medicines tested in the dissolution study.

| Formulation | Strength (mg) | Type (Tablet/Capsule) | Expiry date | Batch No. | Manufacturer |
|-------------|---------------|-----------------------|-------------|-----------|--------------|
| Xeloda®     | 500           | Tablet                | 10/2012     | X0115B01  | Roche (Mexico) |
| Capeda      | 500           | Tablet                | 12/2012     | LT6026    | BPI (Lebanon)  |

### Table 2: In-vitro dissolution procedures for the tested medicines.

| Time (minutes) | Run 1 (%) | Run 2 (%) | Run 3 (%) | Run 4 (%) | Mean (%) | Standard deviation (%) | Coefficient of variation (%) |
|----------------|-----------|-----------|-----------|-----------|----------|------------------------|-------------------------------|
| 5              | 15.9%     | 17.2%     | 30.6%     | 25.3%     | 22%      | 6.9%                   | 31.2%                         |
| 10             | 41.6%     | 44.2%     | 86.1%     | 52.8%     | 51%      | 11.0%                  | 21.5%                         |
| 15             | 63.2%     | 68.2%     | 84.1%     | 68.7%     | 71%      | 9.1%                   | 12.8%                         |
| 20             | 78.7%     | 80.5%     | 92.4%     | 82.2%     | 83%      | 6.1%                   | 7.4%                          |
| 30             | 94.7%     | 93.4%     | 98.5%     | 93.7%     | 95%      | 2.4%                   | 2.5%                          |
| 45             | 100.7%    | 100.4%    | 100.0%    | 98.7%     | 100%     | 0.9%                   | 0.9%                          |
| 60             | 100.7%    | 99.9%     | 100.7%    | 98.7%     | 100%     | 0.9%                   | 0.9%                          |

### Table 3: The percentage of Xeloda® 500 mg dissolved at 60 minutes.

| Time (minutes) | Run 1 (%) | Run 2 (%) | Run 3 (%) | Run 4 (%) | Mean (%) | Standard deviation (%) | Coefficient of variation (%) |
|----------------|-----------|-----------|-----------|-----------|----------|------------------------|-------------------------------|
| 5              | 73.9%     | 51.6%     | 60.9%     | 63.9%     | 63%      | 9.2%                   | 14.6%                         |
| 10             | 85.5%     | 72.5%     | 77.3%     | 77.2%     | 78%      | 5.4%                   | 6.9%                          |
| 15             | 87.8%     | 76.9%     | 85.8%     | 82.0%     | 83%      | 4.8%                   | 5.8%                          |
| 20             | 87.5%     | 78.3%     | 87.2%     | 83.2%     | 84%      | 4.3%                   | 5.1%                          |
| 30             | 87.2%     | 78.0%     | 88.4%     | 83.8%     | 84%      | 4.7%                   | 5.6%                          |
| 45             | 87.7%     | 79.2%     | 91.0%     | 85.0%     | 86%      | 5.0%                   | 5.8%                          |
| 60             | 87.2%     | 79.6%     | 91.9%     | 86.7%     | 86%      | 5.0%                   | 5.8%                          |

### Table 4: The percentage of Capeda 500 mg dissolved at 60 minutes.

| Drug Name     | Average weight (g) | % of drug dissolved at 60 minutes | 95% Confidence Interval | P Value |
|---------------|---------------------|----------------------------------|-------------------------|---------|
| Xeloda® 500 mg| 0.63751             | 100                              | (80- 93)                | 0.003   |
| Capeda 500 mg | 0.98755             | 86                               |                         |         |

**Table 5: The percentages of the dissolution rate of the copy medicines (Capeda) compared to their branded counterpart (Xeloda) at 60 minutes.**
(depth) of its intended copy Capeda 500 mg. (Figure 4). The sizes of tablets were measured using Electronic Digital Calliper [40]. Moreover, Capeda 500 mg showed poorer clarity of solution and presence of undissolved residue and particles during the dissolution test compared to its branded counterpart Xeloda® 500 mg (Figure 5).

Discussion

According to the result of this study, the dissolution rate profile of the branded Xeloda® 500 mg and its intended copy Capeda 500 mg complied with the pharmacopeial limits [37]. All of the tested medicines achieved 85% dissolution at 60 minutes or less. This is found to be compatible with the EMA and the FDA guidance for industry [1,16]. Two-points dissolution specification were selected in this study to ensure 85% dissolution in order to characterise the quality of all the tested products [16]. This can reflect that the in-vivo bioavailability of these products would be similar to that of their branded counterparts Xeloda® 500 mg (Figure 5). The intended copy in this study showed poorer clarity of solution and presence of un-dissolved residue and particles compared to its branded counterpart Xeloda® 500 mg (Figure 5).

of 26% of patients declared that the main reason causing the difficulty in swallowing was the size of the tablet followed by the surface, form and the taste of the tablet [42]. Another study in the literature has confirmed that medicine adherence was greatly influenced by the decline of swallowing ability especially for elderly and patients with oesophageal diseases [43]. This indicates the potential impact of the tablet size on patients' compliance and adherence as well as the clinical outcomes.

The intended copy in this study showed poorer clarity of solution and presence of un-dissolved residue and particles compared to its branded counterparts. This, however, might impact patient safety by increasing the drug’s side effects and drug interactions. According to the literature, particles, degradation products and residual solvents all pose potential threats to patient safety [44]. A study in the literature, for example, was conducted to compare the pharmaceutical quality of 34 generic formulations of ceftriaxone (antibiotic agent) to their branded counterpart Rocephin®. It was found that all the 34 tested generic medicines failed to meet Roche specifications for Rocephin®. A total of 18 generics tested in this study contained more than five times the number of particles found in their branded counterparts and violated the quality standards specified in the European and the US Pharmacopoeias. The most common failures amongst generic medicines were clarity of solution. It concluded that none of the generics tested in this study can be considered pharmaceutically equivalent to Rocephin® [44].

Findings in this article are compatible with others in the existing literature [7,8,45,46]. For example, a study evaluated the quality of 31 commercially available generic formulations of docetaxel obtained from 14 countries revealed that the most tested generic formulations contained a lower amount of docetaxel and/or high level of impurities and did not comply with the original branded specifications compared to the innovator product Taxotere® [47]. Another study compared
A similar study had compared 13 generic alendronate preparations from Latin-America with the innovator product. It revealed that nine of these drugs was questioned [45].

Another dissolution study was performed to evaluate and compare 25 internationally available piroxicam (non-steroidal anti-inflammatory drug) products using the US Pharmacopeial specifications. It revealed that 72% of the tested products failed to meet the USP requirement, several by a wide margin. Also, when the dissolution test for the capsules was applied to five different formulations of piroxicam tablets, 80% of the tablets failed to meet the USP requirement [56].

Conclusion

The results of this study clearly raise a question about the interchangeability between the branded Xeloda® 500 mg and its intended copy Capeda 500 mg in treating cancer patients. Awareness of these scientific concerns should be considered when a clinical choice between these two products is required. This is strongly suggesting the need to monitor patients after performing substitution of these two medicines. The results of this study show that differences may exist between the innovator and copy drugs with regard to pharmacokinetics, clinical efficacy and safety. Therefore, healthcare providers should take into account that definitely generics and copies save money; but are they good for us?

Main limitations of the study

The dissolution test is used to forecast the in-vivo behaviour of a drug. However, definite conclusions about the bioavailability and bioequivalence of these products should be conducted in in-vivo studies. It is critical that the in-vitro test should mimic the in-vivo
conditions as closely as possible. Given the nature of the human GI tract and various factors that affect its activity, the generalisation of dissolution conditions and results of this study are not recommended. *In-vivo* comparison studies are required to demonstrate findings in this study.

**Competing Interests**

This study was funded by the William Harvey Research Institute at Queen Mary University of London. The authors have no financial or proprietary interest in the subject matter or material discussed.

**Acknowledgement**

Authors are grateful to the William Harvey Research Institute at Queen Mary University of London for supporting and encouraging independent research.

**References**

1. European Medicines Agency (2001) Note for guidance on the investigation of bioavailability and bioequivalence.
2. Suh DC (1999) Trends of generic substitution in community pharmacies. Pharm World Sci 21: 260-262.
3. Simoens S (2011) General and therapeutic substitution: ethics meets health economics. Int J Clin Pharm 33: 469-470.
4. Andersson K, Sørensson C, Petzold M, Carlsten A, Lönnroth K (2005) What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 14:341-348.
5. Haas JS, Phillips KA, Gerstenberger EP, Seger AC (2005) Potential savings from substitution generic drugs for brand drugs: Medical Expenditures Panel Survey 1997-2000. Ann Intern Med 142: 891-897.
6. Tilson L, Bennett K, Barry M (2005) The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland. Eur J Health Econ 6: 267-273.
7. Adgebolagun OA, Olaiade O A, Osumah SE (2007) Comparative evaluation of the biopharmaceutical and chemical equivalence of some commercially available brands of ciprofloxacin hydrochloride tablets. Tropical Journal of Pharmaceutical Research 6: 737-745.
8. Al Ameri MN, Whittaker C, Tucker A, Yaqoob M, Johnston A (2011) A survey to determine the views of renal transplant patients on generic substitution in the UK. Transpl Int 24: 770-779.
9. Guo JH, Harcum WW, Skinner GW, Dluzneski PR, Trumbull DE (2000) Validation of tablet dissolution method by high-performance liquid chromatography. Drug Dev Ind Pharm 26: 337-342.
10. Savajer A, Ozkan Y, Işımer A (2005) Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium. Farmaco 60: 171-177.
11. Technical Brief (2010) In-vitro Dissolution Testing for Solid Oral Dosage Forms. Particle Sciences, Drug Development Services 5.
12. Oliveira ÉdFS, Azevedo RdCP, Bonfílio R, Oliveira DBd, Ribeiro GP, et al. (2009) Dissolution test optimization for meloxicam in the tablet pharmaceutical form. Braz J Pharm Sci 45: 67-73.
13. Pharmainfo.net (2008) Dissolution.
14. Dressman JB, Amidon GL, Reppas C, Shah VP (1998) Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms. Pharm Res 15: 11-22.
15. Walley T, Haycox A, Boland A, Pharmacoeconomics (2004) Churchill Livingston 104-105.
16. Food and Drug Administration. (1997) Guidance for industry: Dissolution testing of immediate release solid oral dosage forms.
17. European Medicines Agency. European public assessment report (EPAR), Xeloda.
18. Quinney SK, Sanghani SP, Davis WI, Hurley TD, Sun Z, et al. (2005) Hydrolysis of Capecitabine to 5′-Deoxy-5-fluorocytidine by Human Carbboxylesterases and Inhibition by Loperamide. J Pharmacoel Exp Ther 313: 1011-1016.
19. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, et al. (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281.
20. Schüller J, Cassidy J, Dumont E, Roos B, Durston, et al. (2000) Preferential activation of capetabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297.
21. Regnier B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capetabine. Clin Pharmacokinet 40: 85-104.
22. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, et al. (2005) Capecitabine as Adjuvant Treatment for Stage III Colon Cancer. N Engl J Med 352: 2696-2704.
23. Twelves C, Collins S, Grieve R, Samuel L (2006) A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17: 239-245.
24. Verso M, Agnelli G (2003) Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients. J Clin Oncol 21:3665-3675.
25. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, et al. (2004) Oral capecitabine vs intravenous 5-fluoruracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 90: 1190-1197.
26. Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, et al. (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13: 566-575.
27. Pharmaguide Lebanon (2010) Capeda 500 mg.
28. MainPlus Chemicals Ltd. (UK) (2012) Capecitabine.
29. Kamangar F, Dores GM, Anderson WF (2006) Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. J Clin Oncol 24: 2137-2150.
30. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488.
31. American Cancer Society. Cancer facts and figures 2010.
32. American Cancer Society. Global Cancer Facts & Figures 2007.
33. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer Statistics, 2005. CA: A Cancer Journal for Clinicians 55: 10-30.
34. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, et al. (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 347: 1407-1412.
35. Pharma Test. PT-DT70.
36. Cox D, Douglas C, Furman W, Kirchofer R, Myrick J, et al. (1978) Guidelines for dissolution testing.
37. The United states Pharmacopoeia Convention (2010) US Pharmacopoeia 8: 2505-3504.
38. Al Ameri MN, Nayuni N, Anil Kumar KG, Perrett D, Tucker A, et al. (2012) The differences between the branded and generic medicines using solid dosage forms: *in-vitro* dissolution testing. Results in Pharma Sciences 2: 1-8.
39. European Medicines Agency (1995) Note for guidance on validation of analytical procedures: Text and methodology.
40. http://www.maplin.co.uk/electronic-digital-calliper-32198
41. Makama JG, Ameh EA (2011) Quality of teaching provided by surgical prescribers, patients and pharmacies during the first year of generic substitution. J Clin Pharm 52: 238-242.
42. Gill JS, O’May FP (2011) Is it my job? Alcohol brief interventions: knowledge and attitudes among future health-care professionals in Scotland. Alcohol Alcohol 46: 441-450.
43. Hsu LY, Jin J, Ang BS, Kurup A, Tambiyah PA (2011) Hand hygiene and infection control survey pre- and peri-H1N12009 pandemic: knowledge and perceptions of final year medical students in Singapore. Singapore Med J 52: 485-490.
44. Freemantle N, Mason J (1997) Publication bias in clinical trials and economic analyses. Pharmacoeconomics 12: 10-16.

45. Bertocchi P, Antoniella E, Valvo L, Alimonti S, Memoli A (2005) Diclofenac sodium multisource prolonged release tablets-a comparative study on the dissolution profiles. J Pharm Biomed Anal 37: 679-685.

46. Fernando N, McAdam T, Youngson G, McKenzie H, Cleland J, et al. (2007) Undergraduate medical students’ perceptions and expectations of theatre-based learning: how can we improve the student learning experience? Surgeon 5: 271-274.

47. Vial J, Cohen M, Sassiat P, Thiébaut D (2008) Pharmaceutical quality of docetaxel generics versus originator drug product: a comparative analysis. Curr Med Res Opin 24: 2019-2033.

48. Epstein S, Cryer B, Ragi S, Zanchetta JR, Walliser J, et al. (2003) Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 19: 781-789.

49. Lamprecht G (2009) In vitro determination of the release of alendronic acid from alendronate tablets of different brands during deglutition. J Pharm Sci 98: 3575-3581.

50. Iheanacho I, Blythe J (2009) What are excipients doing in medicinal products?.

51. Wandel C, Kim RB, Stein CM (2003) “Inactive” excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther 73: 394-396.

52. Guzik L, Mrozik W, Kamsyz W (2010) Determination of simvastatin in pharmaceutical dosage forms by optimized and validated method using HPLC/UV. Croat Chem Acta 83: 371–377.

53. Joshi V, Blodgett J, George J, Brinker J (2008) Impact of sample preparation on dissolution testing: Drug binding and extractable impurities and their effect on dissolution data.

54. Dokoumetzidis A, Macheras P (2006) A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int J Pharm 321: 1-11.

55. Pabla D, Akhlaghi F, Zia H (2009) A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm 72:105-110.

56. Barone JA, Lordi NG, Byerly WG, Coiaizzi JL (1988) Comparative dissolution performance of internationally available piroxicam products. Drug Intell Clin Pharm 22: 35-40.